GlassScriptPhysician profile
Laine Keyser
NPI 1902262777
$3,212.12
in general payments reported to CMS, 2019-2025
20 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $452 · 2024: $1,236 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197 · Education: $14.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.21 |
| Education | $14.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.95 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $512.48 | 2023-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $458.49 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $340.12 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $223.62 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $201.02 | 2023-2025 | |
| Janssen Biotech, INC. | $181.67 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $142.94 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $105.62 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $68.61 | 2024-2025 | Resmetirom, Rezdiffra |
| Celltrion USA INC. | $51.12 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $47.98 | 2023-2024 | Zeposia |
| Braintree Laboratories, INC. | $45.93 | 2023-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $44.06 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $40.53 | 2024 | Iqirvo, Bylvay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.82 | 2023 | |
| Phathom Pharmaceuticals, INC. | $31.98 | 2024-2025 | Voquezna |
| Organon LLC | $15.45 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.89 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $13.84 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laine Keyser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.